Catalogo dei prodotti della ricerca

FAZI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.651
AS - Asia 1.129
EU - Europa 1.128
SA - Sud America 149
Continente sconosciuto - Info sul continente non disponibili 142
AF - Africa 48
OC - Oceania 2
Totale 4.249
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.575
IT - Italia 723
SG - Singapore 403
CN - Cina 185
VN - Vietnam 167
HK - Hong Kong 134
BR - Brasile 107
DE - Germania 103
IN - India 70
BD - Bangladesh 62
SE - Svezia 48
FI - Finlandia 47
CA - Canada 37
FR - Francia 36
GB - Regno Unito 36
NL - Olanda 26
JP - Giappone 24
AR - Argentina 21
RU - Federazione Russa 19
BG - Bulgaria 15
AT - Austria 13
ID - Indonesia 12
PH - Filippine 12
ZA - Sudafrica 12
KR - Corea 10
CO - Colombia 9
ES - Italia 9
TR - Turchia 9
BE - Belgio 8
JM - Giamaica 8
RO - Romania 8
EG - Egitto 7
UA - Ucraina 7
IQ - Iraq 6
MA - Marocco 6
SA - Arabia Saudita 6
IE - Irlanda 5
MX - Messico 5
PK - Pakistan 5
VE - Venezuela 5
CR - Costa Rica 4
HN - Honduras 4
IL - Israele 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DZ - Algeria 3
GT - Guatemala 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
PR - Porto Rico 3
SN - Senegal 3
TG - Togo 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AL - Albania 2
AU - Australia 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
GD - Grenada 2
NO - Norvegia 2
PL - Polonia 2
PY - Paraguay 2
RS - Serbia 2
SC - Seychelles 2
SV - El Salvador 2
TH - Thailandia 2
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BT - Bhutan 1
BY - Bielorussia 1
CL - Cile 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GP - Guadalupe 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KW - Kuwait 1
LI - Liechtenstein 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MT - Malta 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
TN - Tunisia 1
Totale 4.107
Salva come PNG Salva come JPEG
Città #
Ashburn 224
Singapore 203
San Jose 194
Rome 137
Milan 132
Hong Kong 124
Fairfield 105
Florence 67
Woodbridge 61
Ho Chi Minh City 60
Munich 50
Seattle 50
Santa Clara 48
Los Angeles 47
Cambridge 46
Chandler 45
Dallas 43
Houston 43
Hanoi 42
Beijing 41
Council Bluffs 30
New York 30
Wilmington 28
Turku 25
Cosenza 24
Buffalo 22
The Dalles 22
Tokyo 22
Ann Arbor 21
Figino 20
Frankfurt am Main 18
Lauterbourg 18
Naples 16
Princeton 16
Helsinki 14
Nuremberg 14
Redondo Beach 14
Sofia 14
Toronto 14
Bengaluru 13
Hillsboro 13
Palermo 12
Hefei 11
London 11
Chicago 10
Phoenix 10
São Paulo 9
Da Nang 8
Denver 8
San Paolo di Civitate 8
Amsterdam 7
Boardman 7
Brussels 7
Genoa 7
Lappeenranta 7
Paris 7
Plano 7
San Diego 7
Udine 7
Bologna 6
Johannesburg 6
Millbury 6
Mumbai 6
Orem 6
Atlanta 5
Bogotá 5
Boston 5
Bremen 5
Casablanca 5
Dublin 5
Jakarta 5
Las Vegas 5
Lawrence 5
Seoul 5
Turin 5
Vienna 5
Bergamo 4
Bến Tre 4
Cape Town 4
Contagem 4
Davao City 4
Falkenstein 4
Federal 4
Livorno 4
Moscow 4
Ottawa 4
Shanghai 4
Abidjan 3
Acerra 3
Andover 3
Augusta 3
Bari 3
Cairo 3
Campinas 3
Campodarsego 3
Cardiff 3
Casier 3
Chennai 3
Clementon 3
Cleveland 3
Totale 2.493
Salva come PNG Salva come JPEG
Nome #
Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis 290
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 260
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL1509 protocol 258
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world 172
Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes 169
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials 160
Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 147
High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial 141
Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the randomized phase III EORTC-GIMEMA AML-19 Trial 138
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial 137
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia 135
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 132
Mitoxantrone, Etoposide and Intermediate-dose Ara-c (mec) - An Effective Regimen For Poor Risk Acute Myeloid-leukemia 128
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE 123
A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era 122
Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol 108
Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996 103
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT 100
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial 96
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients 93
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients 92
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 86
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 85
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 74
Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease 70
Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies 66
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint 65
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 63
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey 61
null 58
null 55
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia. Insights from Italian real‐world practice 52
null 51
null 50
null 43
null 43
Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial 40
null 40
First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients 36
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists 35
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database 34
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial 23
Health‐related quality of life and symptom profile of patients with BCR::ABL1‐negative myeloproliferative neoplasms: Real‐world evidence from the GIMEMA‐PROPHECY observational study 11
null 4
Totale 4.249
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.319
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.319
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022206 0 0 0 13 30 10 8 11 19 20 72 23
2022/2023232 31 21 5 18 17 24 11 23 41 4 14 23
2023/2024314 31 22 24 49 36 66 12 8 5 33 10 18
2024/2025802 30 41 16 39 64 47 40 52 135 58 83 197
2025/20261.780 191 76 113 115 227 90 240 76 215 211 92 134
2026/2027477 118 167 191 1 0 0 0 0 0 0 0 0
Totale 4.249